Preparing for 10 Trends That Will Impact Managed Care Pharmacy
There are 10 emerging healthcare trends that will impact managed care pharmacy organizations over the next 5 years as the United States healthcare system places more emphasis on affordability, population health, and patient satisfaction and quality of care, according to a new report from the Academy of Managed Care Pharmacy.
Price Tags On Healthcare? Only In Massachusetts
Without much fanfare, Massachusetts launched a new era of healthcare shopping last week. Anyone with private health insurance in the state can now go to his or her health insurer’s website and find the price of everything from an office visit to an MRI to a Cesarean section. For the first time, healthcare prices are public.
Financial Results Reveal Why ACOs Left Pioneer Program
CMS released financial results from the first 2 years of the Pioneer ACO program. The program is down to 19 accountable care organizations from the original 32 that started the program, and the financial results reveal why those that dropped out did so.
Turning Big Data into Actionable Wisdom
Although people seem to assume Big Data will answer all questions and improve quality of care while increasing efficiencies, the healthcare industry needs to focus on what data is actually actionable, according to John Halamka, MD, chief information officer at Beth Israel Deaconess.
Cancer and Mental Health
Results of a large study performed across cancer centers in Germany, published online October 6, 2014 in the Journal of Clinical Oncology
, show that 32% of people with cancer experienced some form of clinically relevant mental health challenge, such as anxiety, depressive and adjustment disorders.
Mitochondrial Uncoupling: A New Approach to Treat Diabetes
A new research study from the Robert Wood Johnson Medical School showed that niclosamide ethanolamine salt (NEN) can burn the excess fat in the liver cells of mice through a process known as mitochondrial uncoupling. Fat accumulation in the liver is a typical characteristic of diabetic patients.
Vosaroxin Fails in Phase 3 AML Trials in the Elderly
Sunesis Pharmaceuticals announced the failure of a phase 3 study Monday morning. The company's experimental drug vosaroxin did not extend survival of elderly patients with advanced acute myeloid leukemia compared to a placebo.